Table 4.

Levels of biomarkers in improved vs non-improved iNPH patents (median and IQ-range)

	Improved	Non-improved
	n = 10	n = 10
NFL (ng/L)	1186 (869–1670)	1085 (699–2432)	ns
APL1β25 (ng/L)	2532 (2174–2958)	2820 (2401–2954)	ns
APL1β27 (ng/L)	1067 (900–1157)	1085 (867–1214)	ns
APL1β28 (ng/L)	1423 (1264–1568)	1458 (1291–1562)	ns
Aβ38 (ng/L)	500 (308–605)	503 (224–677)	ns
Aβ40 (ng/L)	3731 (2642–4740)	3677 (1522–4789)	ns
Aβ42 (ng/L)	241 (155–370)	244 (122–438)	ns
sAPPα (ng/mL)	205 (175–279)	212 (144–297)	ns
sAPPβ (ng/mL)	114 (95–155)	127 (75–181)	ns
YKL40 (ng/mL)	122 (99–153)	134 (84–180)	ns

ns non-significant